207801-52-3 Usage
General Description
N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide is a chemical compound with the molecular formula C12H11BrN2O2S. N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide is a sulfonamide derivative with a 4-methylbenzene ring and a bromopyridine group. It is commonly used in the pharmaceutical industry as a building block in the synthesis of various drugs and bioactive compounds. The presence of the sulfonamide group in the molecule makes it a potential candidate for the development of antimicrobial and antineoplastic agents. Additionally, its bromopyridine moiety can be utilized for the preparation of heterocyclic compounds with biological activity. Overall, N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide is an important chemical intermediate with versatile applications in medicinal and synthetic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 207801-52-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,7,8,0 and 1 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 207801-52:
(8*2)+(7*0)+(6*7)+(5*8)+(4*0)+(3*1)+(2*5)+(1*2)=113
113 % 10 = 3
So 207801-52-3 is a valid CAS Registry Number.
207801-52-3Relevant articles and documents
HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME
-
Paragraph 00123-00125, (2020/07/25)
The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i
FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE
-
Page/Page column 103, (2010/09/18)
The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.
Inhibitors of PI3 kinase
-
Page/Page column 32, (2009/07/10)
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.
